GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArcticZymes Technologies ASA (OSTO:BIOTECO) » Definitions » Cash-to-Debt

ArcticZymes Technologies ASA (OSTO:BIOTECO) Cash-to-Debt : 30.12 (As of Dec. 2024)


View and export this data going back to 2012. Start your Free Trial

What is ArcticZymes Technologies ASA Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. ArcticZymes Technologies ASA's cash to debt ratio for the quarter that ended in Dec. 2024 was 30.12.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, ArcticZymes Technologies ASA could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for ArcticZymes Technologies ASA's Cash-to-Debt or its related term are showing as below:

OSTO:BIOTECO' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.74   Med: 12.08   Max: No Debt
Current: 30.12

During the past 13 years, ArcticZymes Technologies ASA's highest Cash to Debt Ratio was No Debt. The lowest was 1.74. And the median was 12.08.

OSTO:BIOTECO's Cash-to-Debt is ranked better than
66.26% of 1488 companies
in the Biotechnology industry
Industry Median: 7.285 vs OSTO:BIOTECO: 30.12

ArcticZymes Technologies ASA Cash-to-Debt Historical Data

The historical data trend for ArcticZymes Technologies ASA's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

ArcticZymes Technologies ASA Cash-to-Debt Chart

ArcticZymes Technologies ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.62 11.31 12.55 14.19 30.12

ArcticZymes Technologies ASA Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.19 22.94 24.71 27.11 30.12

Competitive Comparison of ArcticZymes Technologies ASA's Cash-to-Debt

For the Biotechnology subindustry, ArcticZymes Technologies ASA's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ArcticZymes Technologies ASA's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ArcticZymes Technologies ASA's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where ArcticZymes Technologies ASA's Cash-to-Debt falls into.



ArcticZymes Technologies ASA Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

ArcticZymes Technologies ASA's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

ArcticZymes Technologies ASA's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ArcticZymes Technologies ASA  (OSTO:BIOTECO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


ArcticZymes Technologies ASA Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of ArcticZymes Technologies ASA's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


ArcticZymes Technologies ASA Business Description

Traded in Other Exchanges
Address
Sykehusveien 23, Tromso, NOR, 9294
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments, Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA followed by Lithuania, Germany, Italy, France, and other countries.

ArcticZymes Technologies ASA Headlines

No Headlines